RECRUITINGPhase 4INTERVENTIONAL
Immune Spatial Features of Guselkumab Cutaneous Response
About This Trial
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
Who May Be Eligible (Plain English)
Who May Qualify: possess a PSSI (psoriasis scalp severity index) of ≥12
Who Should NOT Join This Trial:
1. taking systemic immunosuppressives in the last 4 weeks
2. pregnancy
3. severe weakened immune system (either from genetic or infectious causes).
4. tuberculosis or other active serious infection
5. active systemic malignancy.
6. breast-feeding
7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
8. Males who are trying to conceive
\-
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria: possess a PSSI (psoriasis scalp severity index) of ≥12
Exclusion Criteria:
1. taking systemic immunosuppressives in the last 4 weeks
2. pregnancy
3. severe immunodeficiency (either from genetic or infectious causes).
4. tuberculosis or other active serious infection
5. active systemic malignancy.
6. breast-feeding
7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
8. Males who are trying to conceive
\-
Treatments Being Tested
DRUG
Guselkumab
Guselkumab treatment for \~ 9 months
Locations (1)
University of California San Francisco
San Francisco, California, United States